布地格福吸入气雾剂治疗急性加重高风险慢性阻塞性肺疾病患者的疗效  

Efficacy of Budesonide-Formoterol Inhalation Aerosol in Treating High-Risk Acute Exacerbations of Chronic Obstructive Pulmonary Disease Patients

作　　者：朱艳竞 陈培杰 纪小丽 朱利芹 ZHU Yanjing;CHEN Peijie;JI Xiaoli(Department of Respiratory and Critical Care Medicine,Jing'an District Central Hospital,Shanghai 200040)

机构地区：[1]上海市静安区中心医院呼吸与危重症医学科,上海200040

出　　处：《医学临床研究》2024年第9期1354-1357,共4页Journal of Clinical Research

摘　　要：【目的】探讨布地格福吸入气雾剂治疗急性加重高风险慢性阻塞性肺疾病(COPD)的疗效及其安全性。【方法】160例急性加重高风险COPD患者,随机分为观察组(布地格福吸入气雾剂治疗)和对照组(茚达特罗格隆溴铵吸入粉雾剂用胶囊治疗),每组80例。比较两组患者治疗前及治疗后3个月、6个月的肺功能指标、血气指标、COPD评估测试(CAT)评分、呼吸困难指数(mMRC)评分、运动耐力[6 min步行距离(6MWD)]、生命质量(SGRQ)评分。【结果】治疗3个月、6个月后,观察组患者的肺功能指标、血气指标明显优于对照组(P<0.05);观察组的mMRC评分、CAT评分以及SGRQ量表中的呼吸症状评分低于对照组(P<0.05),6MWD大于对照组(P<0.05),而两组SGRQ量表中的日常活动、疾病症状评分及总分比较,差异无统计学意义(P>0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】布地格福吸入气雾剂治疗急性加重高风险COPD患者的疗效好,且不增加药物不良反应的发生率。【Objective】To investigate the efficacy and safety of Budesonide-Formoterol inhalation aerosol in treating high-risk acute exacerbations of chronic obstructive pulmonary disease(COPD).【Methods】A total of 160 patients with high-risk acute exacerbations of COPD were randomly divided into the observation group(treated with Budesonide-Formoterol inhalation aerosol)and the control group(treated with Indacaterol-Glycopyrronium inhalation powder capsules),with 80 cases in each group.The differences in pulmonary function indicators,blood gas indicators,COPD assessment test(CAT)scores,modified Medical Research Council(mMRC)dyspnea scale scores,exercise endurance[six-minute walk distance(6MWD)]and quality of life(SGRQ)scores before treatment,and at 3 months and 6 months after treatment were compared between the two groups.【Results】After 3 and 6 months of treatment,the pulmonary function indicators and blood gas indicators of the observation group were significantly better than those of the control group(P<0.05).The mMRC,CAT,and respiratory symptom scores in the SGRQ scale of the observation group were lower than those of the control group(P<0.05),and the 6MWD was higher than that of the control group(P<0.05).However,there was no statistically significant difference in daily activities,disease symptoms,and total scores on the SGRQ scale between the two groups(P>0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).【Conclusion】Budesonide-Formoterol inhalation aerosol is effective in treating high-risk acute exacerbations of COPD and it does not increase the incidence of adverse drug reactions.

关 键 词：肺疾病 慢性阻塞性/药物疗法 支气管扩张药/药理学 治疗结果 

分 类 号：R563[医药卫生—呼吸系统]